Use of aspartate aminotransferase to platelet ratio to reduce the need for FibroScan in the evaluation of liver fibrosis

doi:10.4254/wjh.v9.i17.791

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 9, Issue 17

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7721)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-2) series.

Item

Count

PDF

372

WORD

178

HTML

3535

Figures (1-3)

213

Tables (1-2)

242

Sum=4540

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

412

Download

909

Sum=1321

Publishing Process of This Article

Item

Count

Browse

792

Download

1068

Sum=1860

Jun 18, 2017 (publication date) through Nov 5, 2024

Times Cited of This Article

Times Cited (9)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Hepatol. Jun 18, 2017; 9(17): 791-796
Published online Jun 18, 2017. doi: 10.4254/wjh.v9.i17.791

Table 2 Performance indicators of aspartate aminotransferase to platelet ratio score 1.0 and FibroScan for advanced fibrosis

	APRI	FibroScan
Sensitivity	51.9%	63.0%
Specificity	84.9%	84.0%
PPV	46.7%	50.0%
NPV	87.4%	89.9%
Accuracy	78.2%	79.7%

NPV: Negative predictive values; PPV: Positive predictive values; APRI: Aspartate aminotransferase to platelet ratio.

Citation: Wong S, Huynh D, Zhang F, Nguyen NQ. Use of aspartate aminotransferase to platelet ratio to reduce the need for FibroScan in the evaluation of liver fibrosis. World J Hepatol 2017; 9(17): 791-796
URL: https://www.wjgnet.com/1948-5182/full/v9/i17/791.htm
DOI: https://dx.doi.org/10.4254/wjh.v9.i17.791